Are You Missing Hidden Toxicity in Your Drug Candidates?

A Safer Way to Trap Reactive Metabolites

In drug discovery, one of the most elusive threats to compound safety is the formation of reactive metabolites – short-lived, unstable molecules that can bind to proteins and DNA, triggering toxic effects. These reactive intermediates are often responsible for idiosyncratic drug reactions, drug-induced liver injury (DILI), and clinical trial failures.

If you’re in the early stages of drug development, you may be asking: How can we detect these risks before they become costly problems?

The Challenge: Detecting Hard-to-Capture Metabolites

Traditional in vitro metabolite profiling often fails to detect the full spectrum of reactive metabolites, especially hard electrophiles like iminium ions. These compounds can form toxic adducts, disrupt protein function, and even provoke immune responses. Yet, many standard trapping protocols rely on potassium cyanide (KCN) – a highly toxic reagent that poses serious safety and handling concerns.

A Safer, Smarter Alternative

Eurofins Discovery has developed an innovative method that traps reactive metabolites without using potassium cyanide. Instead, the approach generates hydrogen cyanide (HCN) in situ through the metabolism of acetonitrile by CYP2E1 enzymes. This allows for the safe and effective trapping of hard electrophiles in a controlled lab setting.

To further improve accuracy, the method incorporates Tris buffer to quench formaldehyde and prevent the formation of metabonates – false positives caused by non-enzymatic reactions. This ensures that only true enzymatic adducts are detected, giving researchers a clearer picture of a compound’s reactivity profile.

Why This Matters for You

If you’re just beginning to explore how to improve safety screening in your pipeline, this method offers a compelling solution. It helps you:

• Detect hidden toxicity risks early, before they derail development.
• Avoid misleading results caused by experimental artifacts.
• Reduce reliance on hazardous reagents, improving lab safety.
• Gain confidence in your compound selection, with more reliable data.

Whether you’re screening for hepatotoxicity, drug-drug interactions, or immune-mediated effects, this cyanide trapping method provides a safer and more accurate way to assess reactive metabolite formation.

Start Building a Safer Pipeline

Early awareness of reactive metabolite risk can transform your development strategy. With the right tools, you can make smarter decisions, reduce attrition, and bring safer therapies to market faster.